Skip to content

Effects of Chamomile With L-theanine Beverage Among Young Women Experiencing Primary Dysmenorrhea

Effects of Chamomile With L-theanine Beverage Among Young Women Experiencing Primary Dysmenorrhea

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07092878
Enrollment
30
Registered
2025-07-30
Start date
2025-03-01
Completion date
2025-07-31
Last updated
2025-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Dysmenorrhea

Keywords

primary dysmenorrhea, sleep, mood

Brief summary

This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.

Detailed description

This study aims to evaluate the effects of a beverage containing chamomile and L-theanine on menstrual symptoms, pain intensity, mood, and sleep quality among young adult females with primary dysmenorrhea.

Interventions

Participants in the intervention group will consume the chamomile with L-theanine (CTT) beverage, which contains 480 mg of chamomile extract and 200 mg of L-theanine.

DIETARY_SUPPLEMENTChamomile

A chamomile-flavored beverage

Sponsors

Universiti Tunku Abdul Rahman
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Intervention model description

Participants in the intervention group will consume a chamomile with L-theanine (CTT) beverage, which will contain 480 mg of chamomile extract and 200 mg of L-theanine. In contrast, those in the control group will consume a chamomile-flavored beverage (non-CTT), which will be flavored with commercial chamomile flavoring.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* A VAS score of ≥4 cm for the past three consecutive menstrual cycles * Regular monthly menstruation * No history of allergies or psychological/gynecological illnesses * Absence of secondary dysmenorrhea * No current use of any medications * No ongoing non-pharmacological management for dysmenorrhea.

Exclusion criteria

* Pregnant * Breastfeeding

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity2 monthsThe pain intensity is assessed using the Visual Analogue Scale (VAS) and the Numeric Rating Scale (NRS). Participants mark the point on the scale (0 to 10) that best represents the average intensity of their menstrual pain. A higher score on the VAS and NRS indicates greater pain intensity.
Menstrual symptoms2 monthsThe Cox Menstrual Symptom Scale (CMSS) is used to assess the severity of menstrual-related symptoms experienced by participants during their most recent menstrual cycle. Each item in the CMSS is rated on a scale from 0 (not noticeable), 1 (slightly bothersome), 2 (moderately bothersome), 3 (severely bothersome), to 4 (very severely bothersome).
Sleep quality2 monthsThe Pittsburgh Sleep Quality Index (PSQI) is used to assess the sleep quality of participants during the past week. The total PSQI score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Mood2 monthsThe Profile of Mood States (POMS) is used to assess six mood subscales (vigor, tension, depression, anger, fatigue, and confusion) of participants during the past week. Each item is rated on a 5-point Likert scale, ranging from 0 (not at all), 1 (a little), 2 (moderately), 3 (quite a lot), and 4 (extremely).

Secondary

MeasureTime frameDescription
Hemoglobin2 monthsHemoglobin is measured in mmol/L

Countries

Malaysia

Contacts

Primary ContactChin Xuan Tan, PhD
tancx@utar.edu.my+605-4688888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026